Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM - nejm.org
- Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM nejm.org
- Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLC OncLive
- New Standard in Operable EGFR-Positive Lung Cancer Medpage Today
- Adjuvant Osimertinib Extends Survival in EGFR-Positive, Stage IB-IIIA NSCLC Targeted Oncology
- Adjuvant Osimertinib Improves Survival in Patients With Resected EGFR-Mutated NSCLC The ASCO Post
- View Full Coverage on Google News